ATE262902T1 - Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose - Google Patents

Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose

Info

Publication number
ATE262902T1
ATE262902T1 AT95939917T AT95939917T ATE262902T1 AT E262902 T1 ATE262902 T1 AT E262902T1 AT 95939917 T AT95939917 T AT 95939917T AT 95939917 T AT95939917 T AT 95939917T AT E262902 T1 ATE262902 T1 AT E262902T1
Authority
AT
Austria
Prior art keywords
lower alkyl
membered heterocyclic
restenosis
atherosclerosis
cancer
Prior art date
Application number
AT95939917T
Other languages
English (en)
Inventor
Neill A Giese
Nathalie Lokker
Alan M Laibelman
Robert M Scarborough
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE262902T1 publication Critical patent/ATE262902T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT95939917T 1994-11-10 1995-11-09 Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose ATE262902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33763094A 1994-11-10 1994-11-10
PCT/US1995/014723 WO1996014843A2 (en) 1994-11-10 1995-11-09 Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases

Publications (1)

Publication Number Publication Date
ATE262902T1 true ATE262902T1 (de) 2004-04-15

Family

ID=23321325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939917T ATE262902T1 (de) 1994-11-10 1995-11-09 Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose

Country Status (13)

Country Link
US (1) US5916908A (de)
EP (1) EP0788358B1 (de)
JP (1) JPH10509708A (de)
KR (1) KR970706813A (de)
CN (1) CN1165482A (de)
AT (1) ATE262902T1 (de)
AU (1) AU700964B2 (de)
CA (1) CA2203517A1 (de)
DE (1) DE69532817T2 (de)
ES (1) ES2219670T3 (de)
MY (1) MY113208A (de)
TW (1) TW474810B (de)
WO (1) WO1996014843A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0738268B1 (de) * 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
CA2273102A1 (en) * 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Urea derivatives
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
CA2274593A1 (en) * 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
CA2274594C (en) 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
EP0946523A1 (de) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Kondensierte polycyclische 2-aminopyrimidinderivate, ihre herstellung und verwendung als proteininhibitoren von tyrosinkinase
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP2001518501A (ja) 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
CN1278724A (zh) 1997-10-06 2001-01-03 巴斯福股份公司 抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US6376527B1 (en) 1998-05-05 2002-04-23 Syntex (U.S.A.) Llc Pyrazole derivatives-p38 map kinase inhibitors
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
WO2001012189A1 (en) 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DK1268472T3 (da) * 2000-02-07 2004-12-06 Bristol Myers Squibb Co 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
MXPA02010222A (es) * 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
WO2002012250A2 (en) * 2000-08-09 2002-02-14 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
DE60110802T2 (de) 2000-08-18 2005-10-06 Agouron Pharmaceuticals, Inc., San Diego Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0209774A (pt) 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
BR0213562A (pt) * 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
AR042067A1 (es) 2002-11-27 2005-06-08 Bayer Pharmaceuticals Corp Derivados de anilinopirazol utiles en el tratamiento de la diabetes
WO2004056806A1 (en) 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7592361B2 (en) * 2003-04-28 2009-09-22 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
EP1633349A1 (de) * 2003-05-02 2006-03-15 Elan Pharmaceuticals, Inc. 4-bromo-5- (2-chlorobenzoylamino)-1h-pyrazol-3-carbonsäure (1-(aminocarbonyl) eth-1-yl) amid-derivate und verwandte verbindungen als bradykinin-b1-rezeptorantagonisten zur behandlung von entzündlichen erkrankungen
JP2006525361A (ja) * 2003-05-02 2006-11-09 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体アンタゴニストとしての選択された置換ピラゾール誘導体および関連化合物
JP2006526015A (ja) 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
EP1667983A4 (de) * 2003-09-23 2010-07-21 Merck Sharp & Dohme Pyrazolmodulatoren von metabotropen glutamatrezeptoren
US7592340B2 (en) * 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
KR100875870B1 (ko) 2004-10-14 2008-12-26 에프. 호프만-라 로슈 아게 항암제로서의 신규 아자인돌 티아졸리논
CN101084214A (zh) * 2004-11-17 2007-12-05 迈卡纳治疗股份有限公司 激酶抑制剂
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
ATE542814T1 (de) * 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CA2668429A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
ES2347721T3 (es) * 2006-12-19 2010-11-03 Vertex Pharmaceuticals, Inc. Aminopirimidinas utiles como inhibidores de proteina quinasas.
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2137183B1 (de) * 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EP2134709A1 (de) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridine als proteinkinasehemmer
AU2008226457B2 (en) * 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
MX2009011811A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CA2694381A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP2164842A2 (de) * 2007-05-24 2010-03-24 Vertex Pharmaceuticals Incorporated Als kinaseinhibitoren geeignete thiazole und pyrazole
EP2166849A4 (de) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc Substituierte pyrazol-verbindungen
NZ582879A (en) * 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
MX2011002312A (es) * 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
US20120045459A1 (en) * 2009-05-05 2012-02-23 Van Andel Research Institute Methods for Treating Autophagy-Related Disorders
EP2311823A1 (de) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
ES2791749T3 (es) 2013-03-15 2020-11-05 Verseon Corp Halogenopirazoles como inhibidores de la trombina
LT2968297T (lt) 2013-03-15 2019-01-10 Verseon Corporation Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
CN103232394B (zh) * 2013-05-14 2014-09-24 浙江医药高等专科学校 含吡唑类化合物、其制备方法和用途
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49100080A (de) * 1973-02-01 1974-09-20
US4622330A (en) * 1982-12-20 1986-11-11 Merck & Co., Inc. Antiprotozoal 3-amino or substituted amino pyrazoles
JPH01258695A (ja) * 1988-04-07 1989-10-16 Yamanouchi Pharmaceut Co Ltd （ピラゾリルアミノ）メチレンビス（ホスホン酸）誘導体及びその医薬
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
EP0541486A1 (de) * 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclische Konjugate
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
CZ284157B6 (cs) * 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
US5605820A (en) * 1994-06-23 1997-02-25 Chemgenics Pharmaceuticals, Inc. Production of strains having biological activities by sexual crosses between vegetatively incompatible strains of Aspergillus nidulans

Also Published As

Publication number Publication date
CN1165482A (zh) 1997-11-19
ES2219670T3 (es) 2004-12-01
EP0788358B1 (de) 2004-03-31
JPH10509708A (ja) 1998-09-22
AU700964B2 (en) 1999-01-14
KR970706813A (ko) 1997-12-01
AU4156196A (en) 1996-06-06
TW474810B (en) 2002-02-01
MY113208A (en) 2001-12-31
WO1996014843A2 (en) 1996-05-23
DE69532817D1 (de) 2004-05-06
DE69532817T2 (de) 2005-01-13
EP0788358A2 (de) 1997-08-13
US5916908A (en) 1999-06-29
WO1996014843A3 (en) 1996-05-23
MX9703488A (es) 1998-07-31
CA2203517A1 (en) 1996-05-23

Similar Documents

Publication Publication Date Title
ATE262902T1 (de) Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
PT70662A (en) Novel (piperidinylalkyl)quinazoline derivates
BG104598A (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
FI913640A0 (fi) Foerfarande foer framstaellning av nitriler.
EP0974584A4 (de) Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung
DK328188A (da) Pyridinderivater, deres fremstilling og laegemidler indeholdende forbindelserne
ES384015A1 (es) Procedimiento para la preparacion de un medio regulador delcrecimiento de plantas.
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
ES426135A1 (es) Procedimiento de preparacion de esteres de aril-piperazino-alcanoles.
IT1215298B (it) 2-(eteroalchil)-1,4-diidropiridine ed un processo per la loro produzione.
ES425576A1 (es) Procedimiento para preparar derivados de pirazol.
ES470709A3 (es) Procedimiento para la fabricacion de derivados heterocicli- cos
AU586255B2 (en) Substituted pyridine-1-oxides
ES8207143A1 (es) Procedimiento para la preparacion de derivados de piridina .
HUT45056A (en) Process for producing histamine h under 1 antagonist compounds and pharmaceuticals comprising the same
GB2299334A (en) Metalloproteinase inhibitors
ES8103749A1 (es) Procedimiento para la preparacion de 5,6,7,8-tetrahidropira-zolo (3,4-b)(1,5)diazepin-1h,4h-5,7-dionas
ES451242A1 (es) Un procedimiento para la preparacion de imidazoles.
TW328088B (en) Imidazolidinone derivative and its acid additional salt, for treatment of senile dementia and the process for preparing them
ES442391A1 (es) Procedimiento para preparar acilpiperazinoisoindolinonas.
JPS5283890A (en) Heterocyclic compounds
ES387878A1 (es) Un procedimiento para derivados de benzodiazepina y sales de los mismos.
JPS5283887A (en) Heterocyclic compounds
ES442392A1 (es) Procedimiento para preparar acilpiperazinoisoindolinosas.
ES8106735A1 (es) Procedimiento para la obtencion de vinil-3 cefalosporinas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties